Increased incidence of rheumatoid arthritis after COVID-19.


Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 28 07 2023
accepted: 16 08 2023
medline: 23 10 2023
pubmed: 20 8 2023
entrez: 19 8 2023
Statut: ppublish

Résumé

An increase in the incidence of inflammatory arthritis after COVID-19 has been reported. Since many diseases exhibit population-specific causal effect sizes, we aimed to evaluate the incidence trends of inflammatory arthritis, including rheumatoid arthritis (RA), after COVID-19 in a large admixed Colombian population. Data analysis for this retrospective, population-based cohort study was carried out using the COOSALUD EPS registry. The following codes were selected for analyses: M059, seropositive RA, M069, unspecified RA, M060 seronegative RA, and other RA-related diagnoses: M064, M139, M068, M058, M130 and M053. The study period was limited to January 01, 2018, through December 31, 2022. Incidence rates (IRs) and incidence rate ratios (IRRs) were assessed. A Cox survival model was built to evaluate the influence of age, gender, and COVID-19 vaccination status on the development of inflammatory arthritis. A bioinformatic analysis was performed to evaluate the homology between SARS-CoV-2 and autoantigen peptides related to RA. The entire population study comprised 3,335,084 individuals. During the pandemic period (2020-2022) the total IIR for seropositive and unspecified RA were 1.60 (95% CI, 1.16-2.22) and 2.93 (95% CI, 2.04-4.19), respectively, and the IIR for overall RA-related diagnosis was 2.01 (95% CI 1.59-2.53). The age groups hazard ratios (HRs) were increased until the age group of 51-60 years (HR: 9.16; 95% CI, 7.24-11.59) and then decreased slightly in the age group 61 years or older (HR: 5.364; 95% CI, 4.24-6.78) compared to those within 18-30 years. Men were less at risk than women to develop inflammatory arthritis (HR: 0.21; 95% CI, 0.18-0.24). The greater time since COVID-19 diagnosis was associated with a lower likelihood of developing inflammatory arthritis (HR: 0.99; 95% CI:0.998-0.999). Vaccination (all types of COVID-19 vaccines included) did not prevent the development of inflammatory arthritis after COVID-19. Low identity was found between the SARS-CoV-2 ORF1ab antigen and the human antigens Poly ADP-ribose polymerase 14 and Protein mono-ADP-ribosyltransferase PARP9 isoform D (39% and 29%, respectively). In conclusion, our study confirms increased incidence of inflammatory arthritis, including RA, after COVID-19, with the greatest increase occurring before the first year post-covid. Women in their fifties were more susceptible. Further research is required to examine the effectiveness of vaccination in preventing post-COVID inflammatory arthritis and the mechanisms implicated in the development of RA after COVID-19.

Identifiants

pubmed: 37597602
pii: S1568-9972(23)00143-X
doi: 10.1016/j.autrev.2023.103409
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103409

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Juan-Manuel Anaya reports financial support was provided by Coosalud EPS. Juan Sebastian Marin reports a relationship with Coosalud that includes: employment.

Auteurs

Juan Sebastian Marín (JS)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia; Population Health Management Group at Coosalud EPS, Cartagena 130001, Colombia.

Enrique A Mazenett-Granados (EA)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia.

Juan Carlos Salazar-Uribe (JC)

Universidad Nacional de Colombia, Medellín 050001, Colombia.

Mauricio Sarmiento (M)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia.

John Fredy Suárez (JF)

Population Health Management Group at Coosalud EPS, Cartagena 130001, Colombia.

Manuel Rojas (M)

Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA 95616, USA; Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.

Marlon Munera (M)

Medical Research Group (GINUMED), University Corporation Rafael Núñez, Cartagena 130002, Colombia.

Rosalbina Pérez (R)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia.

Claudia Morales (C)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia.

Jorge I Dominguez (JI)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia.

Juan-Manuel Anaya (JM)

Health Research and Innovation Center at Coosalud EPS, Cartagena 130001, Colombia. Electronic address: janaya@coosalud.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH